Article thumbnail

Effect of a fluorinated pyrimidine on cachexia and tumour growth in murine cachexia models: relationship with a proteolysis inducing factor

By H J Hussey, P T Todorov, W N Field, N Inagaki, Y Tanaka, H Ishitsuka and M J Tisdale

Abstract

The fluorinated pyrimidine nucleoside, 5′-deoxy-5-fluorouridine (5′-dFUrd) has been shown to effectively attenuate the progress of cachexia in the murine adenocarcinomas MAC16 and colon 26 as well as in the human uterine cervical carcinoma xenograft, Yumoto. Although concomitant inhibition of tumour growth was observed in all three models this was not sufficient to account for the preservation of body weight. An attempt has been made to correlate the anti-cachectic activity of 5′-dFUrd with the presence of a tumour produced proteolysis-inducing factor (PIF), thought to be responsible for the development of cachexia in the MAC16 model. Two variants of colon 26 adenocarcinoma were employed, clone 20 which produces profound cachexia, and clone 5 which produces no change in body weight in recipient animals. Mice bearing the colon 26, clone 20 variant showed evidence for the presence of PIF in tumour, serum and urine, while there was no evidence for the presence of PIF in tumour or body fluids of mice bearing the clone 5 tumours. Treatment of animals bearing the clone 20 variant with 5′-dF Urd led to the disappearance of PIF from the tumour, serum and urine concomitant with the attenuation of the development of cachexia. The human cervical carcinoma, Yumoto, which also induced cachexia in recipiant animals, showed expression of PIF in tumour, serum and urine in control and vehicle-treated mice, but was absent in mice treated with 5′-dFUrd. Thus in these experimental models cachexia appears to be correlated with the presence of PIF. © 2000 Cancer Research Campaig

Topics: Regular Article
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:2374525
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1991). 5¢-Deoxy-5-flurouridine improves cachexia by a mechanism independent of its antiproliferative action in colon 26 adenocarcinoma-bearing mice.
  2. (2000). 56: 1256–1261.62 HJ Hussey et al British Journal of Cancer
  3. (1990). Anticachectic activity of 5¢-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma.
  4. (1991). Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover.
  5. (1986). Cachectin and tumor necrosis factor as two sides of the same biological coin.
  6. (1991). Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia inhibitory factor.
  7. (1996). Characterization of a cancer cachectic factor.
  8. (1995). Establishment and characterization of cachexia-inducing and non-inducing clones of murine colon 26 carcinoma.
  9. (1992). Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
  10. (1997). Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients.
  11. (1996). Induction of muscle protein degradation and weight loss by a tumor product.
  12. (1997). Induction of muscle protein degradation by a tumour factor.
  13. (1995). Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft.
  14. (1995). Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6.
  15. (1998). Mechanism of muscle protein degradation induced by a cancer cachectic factor.
  16. (1995). Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice.
  17. (1991). Opdenakker G and Billiau A
  18. (1997). Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer.
  19. (1987). Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host.
  20. (1998). Purification and characterization of a tumor lipid-mobilizing factor.
  21. (1988). Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines.
  22. (1996). The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer.
  23. (1989). Therapeutic index: a vital component in selection of anticancer agents for clinical trial.
  24. (1992). Weight loss in a murine cachexia model is not associated with the cytokines tumour necrosis factor-a or interleukin-6.